News

New Section: Publications

We have compiled an overview of imusyn-featured publications.

Felzartamab is partially DTT-resistant

In our new publication ⧉, we examined whether different anti-CD38 antibodies behave in the same way when it comes to mitigating their interference in pre-transfusion testing by DTT.

Interference of therapeutic biologics

In our new review ⧉ we look at how therapeutic biologics targeting CD20, CD38 and CD47 can interfere with serological and pre-transfusion testing.

T Cell Staining Reagent available now

Visit our shop to discover Dyemer, imusyn's novel T cell staining reagent.

Or have a look at our unmatched panel of recombinant HLA class I and class II proteins.

imuPep Class I Peptide Binding Analysis

Our innovative, high-throughput service for you to confirm your target peptides, e.g. in vaccine and cancer research.

New IFU Versions

New versions and languages of the IFU for DaraEx plus are now available (release 2026/06/10).

New versions of the IFU for rBGA are available (release 2025/05).

Certificate Available for Download

EN ISO 13485:2016 + AC:2018 + A11:2021, issued March 30^th, 2026, and Certificate Directive 98/79/EC, issued May 20^th, 2022, can be found here.

Welcome to imusyn.

Our mission is to develop and produce outstanding diagnostic tests in the field of transfusion medicine and organ transplantation. We also support the development of in-vitro diagnostic medical devices and provide customized recombinant protein production.